Hyperbaric Oxygen Therapy Versus High Power Laser for Diabetic Neuropathy (HBOT-HPLT-DPN)
Hyperbaric Oxygen Therapy Versus High Power Laser Therapy On Sensorimotor Functions In Patients With Diabetic Peripheral Neuropathy
The purpose of this study is to compare the clinical effects of Hyperbaric Oxygen Therapy (HBOT) versus High-Intensity Laser Therapy (HPLT) on sensorimotor functions and nerve conduction in patients suffering from painful diabetic peripheral neuropathy.
Participants are divided into three equal groups. The first group receives a traditional physiotherapy program focused on ankle and foot exercises. The second group receives hyperbaric oxygen therapy sessions in addition to the traditional program. The third group receives high-power MLS laser therapy alongside the traditional program. Investigators look at whether either advanced intervention shows superiority in improving nerve functionality and reducing neuropathic pain.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Diabetic peripheral neuropathy (DPN) is a major microvascular complication of diabetes leading to progressive nerve damage and neuropathic pain. This randomized controlled trial evaluates and compares the efficacy of two non-pharmacological interventions: Hyperbaric Oxygen Therapy (HBOT) and High-Intensity Laser Therapy (HPLT).
A total of 66 medically controlled patients with painful diabetic neuropathy are randomly assigned into three equal parallel groups (22 patients per group):
- Control Group (A): Receives a traditional physiotherapy program including foot and ankle ROM exercises, strengthening, and functional walking training for 5 sessions per week for 3 weeks.
- Study Group (B): Receives Hyperbaric Oxygen Therapy (100% oxygen at 2.5 ATA for 60 minutes, totaling 90 minutes per session) for 15 sessions over 3 weeks, combined with the traditional physiotherapy program.
- Study Group (C): Receives High-Power Laser Therapy using a Multiwave Locked System (MLS) laser device (1500 Hz frequency) applied every other day for 9 sessions over 3 weeks, combined with the traditional physiotherapy program.
Assessments are conducted before and after the 3-week treatment period using objective Nerve Conduction Studies (NCS) for the sural and common peroneal nerves, and subjective screening via the Arabic Michigan Neuropathy Screening Instrument (MNSI) score.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypten, 11771
- Kobri El Koba Military Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients diagnosed with type 2 diabetes mellitus for more than 5 years.
- Presence of painful diabetic peripheral neuropathy lasting for more than 6 months.
- Presence of sensory abnormalities, burning pain, and impaired nerve conduction velocity in the lower extremities.
- Medically controlled glycemic status.
- Sufficient cognitive abilities with a Mini-Mental State Examination (MMSE) score greater than 24.
- Fit for hyperbaric pressure therapy with a cardiac ejection fraction (CEF) equal to or greater than 50% and blood pressure equal to or less than 150/90 mmHg.
Exclusion Criteria:
- Peripheral neuropathy resulting from causes other than diabetes (e.g., vitamin B12 deficiency, alcohol abuse, or trauma).
- Severe vascular insufficiency in the lower limbs.
- Uncontrolled medical conditions such as tumors or thyroid dysfunction.
- Pregnancy.
- Presence of metallic implantations or cardiac pacemakers.
- Severe visual, auditory, or cognitive impairment (MMSE score less than 24).
- Chronic obstructive pulmonary disease (COPD) or other contraindications to hyperbaric oxygen therapy.
- History of other neurological diseases (e.g., stroke or multiple sclerosis).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Conventional Physiotherapy
Foot and ankle range of motion (ROM) exercises, strengthening exercises, functional exercises, and walking training (5 sessions per week for 3 weeks). |
Foot and ankle range of motion (ROM) exercises, strengthening exercises, functional exercises, and walking training (5 sessions per week for 3 weeks) |
|
Eksperimentel: Hyperbaric Oxygen Therapy (HBOT)
Conventional physiotherapy program plus HBOT sessions (100% oxygen at 2.5 ATA for 60 minutes, with 15 minutes gradual compression and 15 minutes decompression, totaling 90 minutes per session). 15 sessions over 3 weeks. |
100% oxygen inhalation at 2.5 ATA pressure for 60 minutes inside a hyperbaric chamber.
Andre navne:
|
|
Eksperimentel: High-Power Laser Therapy (HPLT)
Conventional physiotherapy program plus HPLT (MLS laser, M6). Applied every other day for 9 sessions over 3 weeks. Includes a remote foot scan followed by contact application on 7 specific lower extremity areas. |
MLS laser (M6 device) at 1500 Hz frequency, applied every other day for 9 sessions over 3 weeks. Includes a remote foot scan followed by contact application on 7 specific lower extremity areas.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Michigan Neuropathy Screening Instrument (MNSI) score
Tidsramme: Baseline and 3 weeks post-treatment
|
The Michigan Neuropathy Screening Instrument (MNSI) questionnaire was used to assess symptoms of diabetic peripheral neuropathy. Abnormal responses were summed to obtain the total score. The questionnaire score ranges from 0 to 13, with higher scores indicating greater neuropathic symptom burden. |
Baseline and 3 weeks post-treatment
|
|
Change in right sural nerve distal sensory latency
Tidsramme: Baseline and after 3 weeks of treatment
|
Right sural nerve distal sensory latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve distal sensory latency
Tidsramme: Baseline and after 3 weeks of treatment
|
Left sural nerve distal sensory latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in right sural nerve sensory amplitude
Tidsramme: Baseline and after 3 weeks of treatment
|
Right sural nerve sensory amplitude was assessed using nerve conduction studies and measured in microvolts (µV). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve sensory amplitude
Tidsramme: Baseline and after 3 weeks of treatment
|
Left sural nerve sensory amplitude was assessed using nerve conduction studies and measured in microvolts (µV). |
Baseline and after 3 weeks of treatment
|
|
Change in right sural nerve conduction velocity
Tidsramme: Baseline and after 3 weeks of treatment
|
Right sural nerve conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve conduction velocity
Tidsramme: Baseline and after 3 weeks of treatment
|
Left sural nerve conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve distal motor latency
Tidsramme: Baseline and after 3 weeks of treatment
|
Right peroneal nerve distal motor latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve distal motor latency
Tidsramme: Baseline and after 3 weeks of treatment
|
Left peroneal nerve distal motor latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve motor amplitude
Tidsramme: Baseline and after 3 weeks of treatment
|
Right peroneal nerve motor amplitude was assessed using nerve conduction studies and measured in millivolts (mV). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve motor amplitude
Tidsramme: Baseline and after 3 weeks of treatment
|
Left peroneal nerve motor amplitude was assessed using nerve conduction studies and measured in millivolts (mV). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve motor conduction velocity
Tidsramme: Baseline and after 3 weeks of treatment
|
Right peroneal nerve motor conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve motor conduction velocit
Tidsramme: Baseline and after 3 weeks of treatment
|
Left peroneal nerve motor conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- P.T.REC/012/005181
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared outside the research team to maintain patient privacy and data confidentiality in accordance with institutional guidelines.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .